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Abstract. Children frequently receive medicines that are designed for adults. The dose of
commercially available products is adapted, mostly based on the child’s bodyweight, thereby
neglecting differences in pharmacokinetic and pharmacodynamics parameters. If commercial
products are unsuitable for administration to children or are unavailable, extemporaneous
pharmacy preparations are a good alternative. For this particular population, orodispersible
ﬁlms (ODFs) can be a highly attractive dosage form for the oral administration of drugs.
ODFs are relatively easy to prepare in a hospital setting, create dose ﬂexibility, and may suit
an individual approach, especially for patients having difﬁculties in swallowing tablets or
being ﬂuid restricted. In this article, various aspects related to pharmacy preparations, clinical
application, and preparation of ODFs for pediatric patients are highlighted and discussed.
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INTRODUCTION
Personalized medicine is becoming increasingly impor-
tant in contemporary pharmacotherapeutics. Children rang-
ing from preterm newborns and neonates via infants and
toddlers to adolescents form an important target group.
Frequently, they receive a medicine that is designed for
adults, a practice called Bunlicensed^ or Boff label use,^ i.e.,
not licensed for that particular purpose. The administered
dose for children is often based on body weight, length, and
gender only, thereby neglecting clinically important differ-
ences in pharmacokinetics (absorption, metabolism, and
elimination of the drug) and pharmacodynamics (changes in
receptor expression). Nowadays, serious attempts are being
made to develop medicines, formulations, and dosage forms
that are adapted to the speciﬁc needs of children. Several
scientiﬁc guidelines have been released by the Food and Drug
Administration (FDA) and the European Medicines Agency
(EMA) concerning the development of medicines for chil-
dren. But there are still hurdles to overcome: the safety of the
excipients, the palatability, and appropriate taste masking
need to be taken into account [1–11].
It has been recognized that children are unable to or have
difﬁculties with swallowing tablets or capsules. Even up to the age
of 18 years, children may have difﬁculties swallowing tablets of
15mmdiameter [12].With adequate training techniques, children
can be taught to swallow smaller tablets. (Un)coated minitablets
with a size of 2–3 mm appear to be well tolerated in trained
children at the age of 6months–6 years [13–16]. However, caution
is needed if coatedminitablets are administered to children below
1 year of age because of incidences of cough during ingestion [15]
and since children tend to chew on them [13]. To circumvent
swallowing problems, tablets are often cut into halves or even
quarters, leading to inaccurate dosing or an altered absorption [2,
17]. Tablets may be crushed and capsules may be opened, only if
they are immediate release products. Most tablets or capsules
with modiﬁed release properties are absolutely unsuitable for this
purpose. Subsequently, the powder can be mixed with a spoonful
of liquid or food. However, parents or caretakers may uninten-
tionally mix the powder with a substance that may alter stability
or inﬂuence absorption [18].
Liquid formulations are a suitable alternative to solid dosage
forms. They are easy to administer and create dose ﬂexibility.
However, there are some limitations related to liquid dosage forms.
Frequently, such dosage forms are too strong for children. On the
other hand, if the available liquid dosage forms are not strong
enough, it is not always possible to achieve the required dosage.
Especially in children suffering from disorders that require ﬂuid
restriction, this is a relevant issue. Furthermore, there is a
considerable risk of under- or overdosing errors. To overcome
these problems and to increase the safety for the patient, e.g.,
reducing chocking risk due to particle inhalation by giving chewing
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tablets, and reducing dosage errors by offering a formulation with
an adapted dose, orodispersible drug formulations such as
orodispersible ﬁlms (ODFs) are an attractive new and innovative
administration form for this particular target group [9, 19].
If commercially available products are unsuitable or
unavailable, extemporaneous preparations can fulﬁll the pa-
tient’s individual need. An important precondition, however, is
that extemporaneous manufacturing is performed under cir-
cumstances that guarantee a good product quality. In hospital
pharmacies or large manufacturing pharmacies, such precondi-
tions can be achieved and thus pediatrics preparations can be
manufactured there for the individual patient [3]. ODFs can be
both commercially prepared and extemporaneously on a small
scale in a hospital setting as pharmacy preparations. According
to the European Pharmacopoeia Eighth Edition (Ph. Eur. 8th
Edition), orodispersible ﬁlms are single- or multilayer sheets of
suitablematerials, to be placed in themouthwhere they disperse
rapidly [20]. ODFs are easy to administer and require almost no
intake of water. ODFs can be cut precisely in any desired dosage
strength with a pair of scissors. Hence, they may suit the
individual approach needed in pediatrics [21, 22].
The focus of this paper is on pharmacy preparations,
clinical possibilities, and preparation of extemporaneously
prepared ODFs to be applied in pediatrics.
PHARMACY PREPARATIONS CREATE FLEXIBILITY
According to the European Pharmacopoeia, pharmacy
preparations include extemporaneous preparations made for an
individual patient or for a small patient population which are
supplied immediately after preparation, as well as stock prepara-
tions which aremade in advance and stored until requested [23]. In
view of this deﬁnition, pharmacy preparations are very suitable to
overcome the problem related to a lack of commercially available
medicines for pediatric patients and the need of tailor-made,
personalizedmedicines for children. Pharmacy preparations can be
compounded from raw materials, made by modiﬁcation or
manipulation of commercially available licensed dosage forms or
prepared prior to use [2, 24]. Figure 1 gives an overview of themain
problems related to the manipulation of commercially available
oral dosage forms and provides some good alternatives.
In The Netherlands, the Royal Dutch Pharmacist Association
(KNMP), the professional organization for pharmacists, has
developed standardized procedures covering various dosage forms
and basic manufacturing processes. They are available online (but
no open access) for Dutch pharmacists and updated on a regular
basis.Many of these standardized procedures are incorporated and
discussed in the book Practical Pharmaceutics, an international
guideline for the preparation, care, and use of medicinal products
[24].ADutch formulary is availablewith standardized formulations
for smaller-scale pharmacy preparations for which no licensed
alternative is available. These formulations yield good and reliable
products if prepared according to the general procedures, thereby
safeguarding general quality. The use of these products is
considered on a beneﬁt to risk evaluation for speciﬁc patient
categories such as pediatric patients. Oral (liquid and solid),
dermal, oropharyngeal, ocular, nasal, rectal, and parenteral
preparations are included in the monographs as well as comments
with relevant background information for each individual formu-
lation. The standardized pharmacy preparations can be applied to
make individual prescriptions or for the preparation of small to
medium stocks. All standardized preparations have been thor-
oughly validated and yield high quality and reproducible products
[25]. Current initiatives by the European Directorate for the
Quality ofMedicines andHealthcare aim to harmonize the speciﬁc
class of pediatric pharmacy preparations [26]. Up till now, ODF
preparations for pediatrics are not available as standardized
formulations. However, research in this ﬁeld is ongoing. Good
qualityODFs containing low-dose enalapril maleate, prednisolone,
or diazepam have been successfully prepared on lab scale which
could be suitable as standardized formulations [21]. Non-
standardized pharmacy preparations are used for single or at most
for a handful of patients. The effectiveness, safety, and quality of
the product should always be evaluated before it is prepared.
Choosing a non-standardized pharmacy preparationmeans that no
formulation is readily available. The design and the technological
production process have to be drafted from scratch and will result
in a product that complies with a minimum set of requirements
regarding composition, quality, stability, and biopharmaceutical
performance. Furthermore, the product’s practical applicability and
ease of use as well as the safety for the patient and the compounder
must be taken into account. Also, the balance between the risk of
non-availability of a medicine and the risk of well-documented
quality of the product should be considered. The pharmacist takes
the ﬁnal responsibility in this respect and has an advising role to the
prescribing physician [25].
GMP CONDITIONS
The production of medicines should be performed under
conditions that guarantee the quality of the product and its
chemical, physical, and microbiological stability. In the
pharmaceutical industry worldwide, strict good manufactur-
ing practice (GMP) conditions are applied [27, 28]. In a
hospital or compounding pharmacy setting where pharmacy
preparations are produced in small batches, a full industrial
GMP process is not feasible. Furthermore, speciﬁc require-
ments unique for a hospital setting are not addressed in the
industrial GMP guidelines [25]. To guide good practices for
Fig. 1. Main problems related to the modiﬁcation of commercially
available oral dosage forms and good alternatives
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the preparation of medicinal products in healthcare estab-
lishments, the Pharmaceutical Inspection Convention in 2008
published the PIC/S guidelines which are being increasingly
used as a reference for pharmacy preparations including
aseptic handling in pharmacies in Europe [24, 29]. In
The Netherlands, the industrial GMP guidelines have been
adapted to ﬁt to the hospital environment to the so-called
GMP-Z, established by the Dutch Hospital Pharmacists
Association (NVZA) in 1996 and revised in 2009–2011 [24,
30]. The GMP-Z encompasses guidelines to ensure that good
quality pharmacy preparations are manufactured in the
hospital under controlled conditions. The GMP-Z also covers
preparation processes that are speciﬁc for a hospital phar-
macy but not described in the industrial GMP [25]. The
hospital speciﬁc preparation processes are described in four
additional chapters: assessment of the requested pharmacy
preparation and the quality of the product design; tailor-made
preparations; aseptic handling; guidelines how to work with
hazardous (starting) materials and products [30].
Tailor-made preparations are deﬁned in the GMP-Z
guideline as preparations intended for one or a few patients
which are supplied immediately and not kept in stock. Such
preparations can be compounded from validated standard-
ized preparation instructions or from non-standardized prep-
aration instructions. ODFs as extemporaneous pharmacy
preparations can be covered by the tailor-made preparations
as deﬁned in this GMP-Z guideline. Validation, in-process
control, and end-control of tailor-made preparations differ
from those for stock preparations. For that reason, all
speciﬁed instructions need to be followed precisely. Besides,
personnel should be qualiﬁed and trained adequately and
continuously [24, 30].
PRESCRIPTION ASSESSMENT
In principle, for each pharmacy preparation, a product
ﬁle needs to be established. In a product ﬁle, all documents
regarding the pharmacy preparation are collected, e.g.,
pharmacotherapeutic rationale, instructions regarding the
preparation, operating- and analytical instructions, and sta-
bility and user information [24]. An important step in the
product ﬁle is the assessment of the therapeutic rationale
which entails the decision whether there is a speciﬁc clinical
need for a particular pharmacy preparation. In other words,
does the pa t i en t beneﬁ t f rom i t i n te rms o f
pharmacotherapeutic outcome and is the patient not exposed
to too much risk. In pediatric formulation development of
new dosage forms such as extemporaneously prepared ODFs,
this is an inevitable step.
Considerations that need to be taken into account are: is
a licensed and commercial product available? Does the
pharmacy preparation have a unique therapeutic value for
the particular patient? Does it improve patient-friendliness
and hence better compliance? Is the pharmacy preparation
safe for the patient? [22, 26, 31] A risk assessment is needed if
an extemporaneous pharmacy preparation is required where
the beneﬁt of the patient and the possible risk involved with
the preparation should be considered in relation to the
appropriate quality level. For each pharmacy preparation,
the quality needs to be assured and preparation methods
should be uniform, reproducible, and well documented.
Documentation is therefore an important part of the quality
system related to pharmacy preparations [24]. Figure 2 gives
an overview of the steps involved in a prescription
assessment.
CLINICAL POSSIBILITIES FOR THE APPLICATION
OF ODFS TO PEDIATRICS
Drugs are administered orally to children not only in the
outpatient setting [32], but also in the hospital. Here, a
substantial proportion of drugs is administered orally even to
children admitted to neonatal and pediatric intensive care
units. The use of oral drugs, as opposed to intravenously
administered drugs, has the advantage of less risk of adverse
effects including infection, less costs, and easier administra-
tion without the need for an inconvenient intravenous access.
In infants and neonates, a liquid formulation is the most
widely used oral dosage form because of the advantage of
dose ﬂexibility combined with a lower risk on choking, as
opposed to solid oral dosage forms.
However, for many drugs commonly used in pediatrics, a
suitable drug formulation or dosage strength is not commer-
cially available. In the past decade, progress has been made
following American and European legislation, to stimulate
pharmaceutical companies to perform studies in children, but
a large proportion of older, generically available drugs, will
not be included in these programs [33, 34]. For many drugs
commonly used in pediatrics, such as antiepileptic drugs
(phenytoin, phenobarbital), diuretics (hydrochlorothiazide,
furosemide and spironolactone), ACE inhibitors (enalapril),
and calcium channel antagonists (nifedipine, amlodipine), no
formulation is commercially available, which is suitable for
use in neonates or small children. For these drugs, oral liquids
have been developed as extemporaneous pharmacy prepara-
tions. However, taste or stability issues or solubility difﬁcul-
ties hamper the applicability of some liquids. As an example,
hydrochlorothiazide is often used as a long-term treatment in
neonates for the treatment of bronchopulmonary dysplasia, a
Fig. 2. Prescription assessment
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chronic lung disorder. Hydrochlorothiazide is soluble up to
0.6 mg/ml in an aqueous environment. Higher concentrations
can only be prepared as a suspension instead of a clear
solution, leading to a potential risk on dosage errors when not
homogenized properly prior to administration. Therefore, a
solution of 0.5 mg/ml hydrochlorothiazide is most often
prepared.
However, the current pediatric dosage of 1–2 mg/kg
orally twice daily results in an undesired high volume intake
when using the 0.5-mg/ml concentration. For these children,
the use of a drug formulation, which combines an easy
administration, dose ﬂexibility with low volume ﬂuid intake
might be beneﬁcial. As such, the use of hydrochlorothiazide
in an ODF might be an important improvement in drug
formulation. ODFs are easy to administer and need almost
no intake of water. Once administered, an ODF sticks to the
tongue or palatal and cannot be spit out thereby improving
patient compliance. Different ODF formulations have
already been developed which are suitable as a starting
point for further research, e.g., ODFs containing caffeine,
dimenhydrinate, enalapril maleate, prednisolone, diazepam,
or ibuprofen [21, 35–37]. The used APIs should be
appropriately taste masked and non-irritable. Due to the
limited drug load per ODF, multiple dosing might be
necessary which might be considered as a disadvantage [8,
9, 22, 31].
In other clinical conditions where volume restriction is
important, ODFs may gain in place in the therapeutic arsenal.
Many cardiovascular drugs are administered to patients in
which the ﬂuid balance is rigidly monitored and carefully
balanced, because of a comprised cardiac output. The limited
volume associated with the use of ODFs may well be an
advantage in its clinical use, as opposed to larger volumes of
liquid.
DEVELOPMENT AND TECHNICAL ASPECTS OF AN
ODF FORMULATION
ODFs can be relatively easily prepared on a small scale
using the solvent casting method. A particular ODF consists
of an active pharmaceutical ingredient (API), a ﬁlm-forming
polymer, or a combination of ﬁlm-forming polymers, a
plasticizer, and various excipients such as ﬂavors, colors,
ﬁllers, saliva-stimulating agents, and, although not often used,
a preservative [22, 38]. All used excipients should be
appropriate and safe for the target group, especially for
children [8, 31]. In brief, the preparation of an ODF using the
solvent casting method is as follows. The API and all
excipients are combined in an appropriate solvent. The API
is preferably dissolved in water but can also be dissolved in a
co-solvent, dissolved as an API-cyclodextrin complex or
ﬁnely dispersed as a suspension [21, 35–38]. After a clear
solution or homogeneous suspension has been obtained, the
casting solution is casted with a desired casting height varying
from 500 to 2000 μm onto a release liner. The release liner is
ﬁxed by vacuum suction on a ﬁlm applicator. The casting
solution is dried on the ﬁlm applicator at low temperature and
subsequently cut into the desired size [21, 22]. Size and drug
content of the initial casting solution will determine the ﬁnal
dose. Besides the solvent casting method, printing of an API
onto a plain ODF is an upcoming manufacturing method
which could become very interesting for the small-scale
production of ODFs [39, 40].
Before ODFs can be prepared as small-scale extempo-
raneous pharmacy preparations for clinical use, the formula-
tion has to be developed, tested, and optimized on a lab scale.
The casting solution must be free from air bubbles, should
contain no lumps of polymers or aggregates of API or
excipients, and should possess a viscosity making it suitable
for casting. The prepared ODFs should be easy to remove
from the release liner, not stick to the ﬁngers during handling
but do stick well to the tongue or palatal, to prevent chocking
in the pediatric patient group, where they disintegrate fast.
They meet the requirements of uniformity of mass and
uniformity of content, possess suitable mechanical properties
(do not break during handling), and show physical, chemical,
and microbiological stability during storage [21, 22]. A current
restriction is the limited drug load per ODF; therefore, only
relatively potent APIs can be used. Up to now, a few studies are
available concerning the acceptance of ODFs. However, it is
assumed that the acceptability is high in children on the
condition that the ODFs have acceptable taste [22].
From various pre-formulation studies, it appeared that
different APIs and dosages may require a speciﬁc composi-
tion of the casting solution. The APIs may inﬂuence the
viscosity of the casting solution to such an extent that the
solution becomes unsuitable for casting and ODF production.
This was most evident for enalapril maleate. For poorly
water-soluble APIs such as diazepam, a co-solvent is needed.
The use of a co-solvent may also negatively inﬂuence the
viscosity of the casting solution. Besides, a test on residual
solvent is needed as oral intake of the solvent is harmful to
the target group. Typically, such problems may require a
different composition of the casting solution [21].
The quality by design (QbD) approach was shown to be
a useful tool to optimize ODF formulations [41]. QbD is a
systemic approach to improve the control over the quality of
the production process and includes the establishment of a
quality target proﬁle [41, 42]. Subsequently, the optimized
formulation can be used for the repetitive production of
ODFs in a hospital setting on a small scale for clinical use. In
such setting, the ODFs need to be prepared under GMP
conditions and rigid quality control should guarantee a
continuously good product. Besides the aforementioned
requirements, an important requirement in the clinic is that
the ODFs are sufﬁciently resistant to damage that may be
caused by handling. ODFs need special air-tight packaging to
maintain integrity and stability. The suitability of aluminum
sachets, foil, paper, or plastic pouches as packaging material
needs to be evaluated carefully [22, 38].
PERSPECTIVE
Pharmacy preparations such as ODFs create more dose
ﬂexibility than achievable with commercially available products
for adults, provide good patient acceptance, and hence increase
patient compliance [22]. ODFs can be cut into separate smaller
pieces for dose adjustment, which is important in pediatrics [21].
ODFs are easy to administer and require almost no intake of
water. This makes ODFs a suitable dosage form for patients who
have difﬁculties swallowing large amounts of ﬂuid, are unable to
swallow (mini)tablets, are non-cooperative, and are prone to
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spitting out drugs or suffer from disease requiring restricted ﬂuid
intake, e.g., oedema or heart failure. This shows the perspectives
for the administration of ODFs to neonates and pediatrics. The
majority of the API will be released in the oral cavity and
subsequently swallowed resulting in a pharmacokinetic proﬁle
compared to an oral solution [22]. However, the ﬁrst-pass
metabolism can be partly circumvented if absorption via the oral
mucosa is promoted. This may improve bioavailability which
entails a risk of overdosing if the ODFs are not administered
correctly. On the other hand, an improved bioavailability may
reduce the dose needed and contribute to a reduction of side
effects [22, 43]. ODFs are also convenient portable dosage forms.
This is an advantage compared to brittle and fragile
orodispersible tablets and liquid dosage forms that demand a
special package for transportation or are only available in large
bottles [43].
Up to now, there are no standard formulations for the
preparation of ODFs available in the Dutch or in any other
national formulary. However, research in this ﬁeld is ongoing
and promising.
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